Health Care·Pharmaceuticals·$3.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.26 | N/A | -16.59% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.26 | N/A | -16.59% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the difficulties faced in the quarter. They emphasized their commitment to ongoing development efforts.
Management did not provide specific guidance for future performance.
The company is focused on advancing its pipeline despite the current challenges.
Edgewise Therapeutics reported a wider-than-expected loss for the quarter, which contributed to a 2.21% decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's near-term prospects. Management's focus on pipeline development suggests they are prioritizing long-term growth despite current challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
US FOODS HLDG CORP
Nov 8, 2021